Completed PHASE2 INTERVENTIONAL 1-arm NCT01553851

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Sponsor: National Comprehensive Cancer Network

Conditions Mouth Neoplasms Neoplasms, Oral

Interventions GSK1120212

Updated 8 times since 2017 Last updated: Oct 31, 2016 Started: Feb 28, 2013 Primary completion: Jun 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Mouth Neoplasms and Neoplasms, Oral, this trial is completed. The trial is conducted by National Comprehensive Cancer Network and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Comprehensive Cancer Network
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States